“For early stages with low tau tangles, anti-amyloid therapies could be more efficacious than in late stages,” Kanta Horie, PhD, co-author and researcher at WashU Medicine, said in the press ...

“We’re about to enter the era of personalized medicine for Alzheimer’s disease,” co-lead researcher Kanta Horie, a research associate professor of neurology at the University of Washington ...

Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, College of Pharmaceutical Sciences, Zhejiang University of Technology, China; Department of Molecular, Cellular, ...

The final season also sees the return of stars Yuya Yagira (“Nobody Knows”), Show Kasamatsu (“Tokyo Vice”), Riho Yoshioka (“House of Ninjas”), Mitsuo Yoshihara (“Or Utopia”), Baijaku Nakamura (“The ...

someone in the world develops dementia every three seconds "We're about to enter the era of personalized medicine for Alzheimer's disease," said co-first author Kanta Horie from WashU Medicine.

"We’re about to enter the era of personalized medicine for Alzheimer’s disease," said co-first authors Kanta Horie, PhD, a research associate professor of neurology at WashU Medicine ...

Researcher Kanta Horie explained the potential shift this brings: "We’re about to enter the era of personalized medicine for Alzheimer’s disease. For early stages with low tau tangles ...

Source Reference: Horie K, et al "Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer's disease" Nat Med 2025; DOI: 10.1038/s41591-025-03617-7.